Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00400569 · OUTCOME

Number of Participants With Overall Response (OR)

Phase II Study of Sunitinib Malate for Metastatic and/or Surgically Unresectable Soft Tissue Sarcoma · Source last updated 2012-08-28

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
participants
Interval / dispersion
Not reported
Time frame
From On Treatment to Off Study - average of 6 months

What was measured

Objective Radiographic Response Rate. Response assessments were based on the longest diameter tumor measurements in accordance with Response Evaluation Criteria in Solid Tumors (RECIST).

Analysis population: All participants assessable for response

Groups in this outcome

Experimental: Sunitinib Malate (SU011248) Treatment

Sunitinib malate, 50 mg daily, for 4 weeks every 6 weeks

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Experimental: Sunitinib Malate (SU011248) Treatment43

Reported measurements

Source class 1
Values in participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Experimental: Sunitinib Malate (SU011248) Treatment1Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        1
denoms
  1. counts
    1. group Id
      OG000
      value
      43
    units
    Participants
description
Objective Radiographic Response Rate. Response assessments were based on the longest diameter tumor measurements in accordance with Response Evaluation Criteria in Solid Tumors (RECIST).
groups
  1. description
    Sunitinib malate, 50 mg daily, for 4 weeks every 6 weeks
    id
    OG000
    title
    Experimental: Sunitinib Malate (SU011248) Treatment
param Type
NUMBER
population Description
All participants assessable for response
reporting Status
POSTED
time Frame
From On Treatment to Off Study - average of 6 months
title
Number of Participants With Overall Response (OR)
type
PRIMARY
unit Of Measure
participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice